Packer M, Lee W H, Kessler P D
Circulation. 1986 Oct;74(4):766-74. doi: 10.1161/01.cir.74.4.766.
When renal perfusion pressure is reduced in experimentally induced low-output states, glomerular filtration rate is preserved by angiotensin II-mediated efferent arteriolar vasoconstriction, but available evidence in man suggests that angiotensin II supports renal function only to the extent that it preserves systemic blood pressure. We performed simultaneous assessments of cardiac and renal function in 56 patients with severe chronic heart failure before and after 1 to 3 months of converting-enzyme inhibition. Among the 29 patients with a pretreatment renal perfusion pressure under 70 mm Hg, patients with preserved renal function (creatinine clearance greater than 50 ml/min/1.73 m2) had markedly elevated values for plasma renin activity (11.8 +/- 3.8 ng/ml/hr) and showed a significant decline in creatinine clearance after converting-enzyme inhibition (61.1 +/- 3.0 to 45.9 +/- 5.3 ml/min/1.73 m2; p less than .05). In contrast, although similar with respect to all pretreatment demographic, hemodynamic, and clinical variables, patients with a creatinine clearance under 50 ml/min/1.73 m2 had low values for plasma renin activity (3.4 +/- 0.8 ng/ml/hr) and, despite similar drug-induced decreases in systemic blood pressure, showed no change in creatinine clearance after therapy with captopril or enalapril (32.6 +/- 2.5 to 41.4 +/- 3.8 ml/min/1.73 m2). Changes in creatinine clearance varied linearly and inversely with pretreatment values for plasma renin activity (r = - .64, p less than .001); converting-enzyme inhibition effectively abolished the pretreatment difference in renal function seen in the high- and low-renin subgroups. In the 27 patients with a renal perfusion pressure of 70 mm Hg or greater, creatinine clearance did not vary significantly with plasma renin activity and was not altered by therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
在实验性诱导的低输出状态下,当肾灌注压降低时,肾小球滤过率通过血管紧张素II介导的出球小动脉血管收缩得以维持,但人类的现有证据表明,血管紧张素II仅在维持全身血压的程度上支持肾功能。我们对56例严重慢性心力衰竭患者在进行1至3个月的转换酶抑制治疗前后同时进行了心脏和肾功能评估。在29例治疗前肾灌注压低于70 mmHg的患者中,肾功能正常(肌酐清除率大于50 ml/min/1.73 m2)的患者血浆肾素活性值显著升高(11.8±3.8 ng/ml/hr),并且在转换酶抑制治疗后肌酐清除率显著下降(61.1±3.0至45.9±5.3 ml/min/1.73 m2;p<0.05)。相比之下,尽管在所有治疗前的人口统计学、血流动力学和临床变量方面相似,但肌酐清除率低于50 ml/min/1.73 m2的患者血浆肾素活性值较低(3.4±0.8 ng/ml/hr),并且尽管药物引起的全身血压下降相似,但在用卡托普利或依那普利治疗后肌酐清除率没有变化(32.6±2.5至41.4±3.8 ml/min/1.73 m2)。肌酐清除率的变化与治疗前血浆肾素活性值呈线性反比关系(r = -0.64,p<0.001);转换酶抑制有效地消除了高肾素和低肾素亚组中治疗前肾功能的差异。在27例肾灌注压为70 mmHg或更高的患者中,肌酐清除率与血浆肾素活性无显著变化,且不受治疗影响。(摘要截断于250字)